RNA:NSD-Avidity Biosciences Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 40.85

Change

0.00 (0.00)%

Market Cap

USD 4.13B

Volume

7.73M

Analyst Target

USD 43.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.53 (+0.54%)

USD 120.95B
REGN Regeneron Pharmaceuticals Inc

-12.36 (-1.17%)

USD 115.81B
MRNA Moderna Inc

+1.12 (+0.97%)

USD 45.51B
ALNY Alnylam Pharmaceuticals Inc

+4.29 (+1.76%)

USD 30.78B
ARGX argenx NV ADR

+1.27 (+0.29%)

USD 26.20B
BNTX BioNTech SE

-0.07 (-0.09%)

USD 20.40B
GMAB Genmab AS

+0.05 (+0.20%)

USD 16.65B
RPRX Royalty Pharma Plc

-0.31 (-1.18%)

USD 15.75B
BGNE BeiGene Ltd

-0.96 (-0.66%)

USD 15.73B
BMRN Biomarin Pharmaceutical Inc

+0.09 (+0.11%)

USD 15.63B

ETFs Containing RNA

DXSP:XETRA Xtrackers - Euro Stoxx 50.. 5.81 % 0.00 %

+0.03 (+-3.35%)

USD 0.05B
GNOM Global X Genomics & Biote.. 5.41 % 0.00 %

-0.09 (-3.35%)

USD 0.09B
GNOG:LSE Global X Genomics & Biote.. 5.20 % 0.00 %

-0.06 (-3.35%)

USD 6.91M
PTH Invesco DWA Healthcare Mo.. 3.96 % 0.60 %

-0.39 (-3.35%)

USD 0.14B
SURI Simplify Propel Opportuni.. 3.41 % 0.00 %

-0.74 (-3.35%)

USD 0.12B
SBIO ALPS Medical Breakthrough.. 2.93 % 0.50 %

-1.00 (-3.35%)

USD 0.10B
MOON Direxion Moonshot Innovat.. 2.33 % 0.00 %

-0.05 (-3.35%)

USD 0.02B
AVSC American Century ETF Trus.. 0.49 % 0.00 %

+0.17 (+-3.35%)

USD 1.08B
IWC iShares Micro-Cap ETF 0.00 % 0.60 %

-0.12 (-3.35%)

USD 0.79B
XSSX:LSE Xtrackers - Euro Stoxx 50.. 0.00 % 0.00 %

+2.55 (+-3.35%)

USD 0.05B
DXSP:F Xtrackers - Euro Stoxx 50.. 0.00 % 0.00 %

+0.05 (+-3.35%)

USD 0.05B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 351.38% 99% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 351.38% 99% N/A 99% N/A
Trailing 12 Months  
Capital Gain 268.35% 99% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 268.35% 99% N/A 99% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -8.03% 48% F 29% F
Dividend Return -8.03% 48% F 28% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.01% 60% D- 36% F
Risk Adjusted Return -17.09% 46% F 32% F
Market Capitalization 4.13B 94% A 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector